Abstract
The GABAergic system is central to the development and functional maturation of the nervous system. Emerging evidence support the role of GABAergic dysfunction in neuro-developmental disorders. This review presents the molecules and mechanisms that underlie GABA system dysfunction in several neuro-developmental disorders presenting in childhood. The impact on synaptic plasticity, neuronal circuit function and behavior, followed by targeted treatment strategies are discussed.
Introduction
Neuronal circuits undergo structural refinement in response to changes in experience. Although this ability is present throughout life, there are sensitive periods of elevated plasticity when the brain is capable of intense restructuring of synaptic connections (Wiesel and Hubel, 1963; Knudsen, 2004; Hensch, 2005). These periods of elevated plasticity occur early in postnatal life and are triggered by a unique excitatory—inhibitory (E/I) balance that sets in motion a cascade of molecular events. These molecular events lead to structural changes and closure of the critical period. Critical periods sub-serving the acquisition of different skills occur on different time scales and in multiple brain regions. While they offer tremendous opportunities, they are periods of great vulnerability for the developing brain and critical period dysfunction is linked to several neuro-developmental disorders.
The complexity of neural circuits results in part from the rhythmic inhibitory activity of GABAergic interneurons that synchronize the spiking of local pyramidal cell ensembles, thus maintaining homeostatic levels of activity in the brain (Somogyi et al., 1998; Markram et al., 2004; Somogyi and Klausberger, 2005; Kullmann, 2011). These processes act to enhance the efficiency of information processing by increasing the likelihood of coincident spiking and action potential firing in downstream neurons.
There are several different classes of GABAergic interneurons. Among them are fast-spiking, parvalbumin (PV) positive basket cells which account for 50% of GABAergic interneurons in rodent cortex and are required for the generation of fast rhythmic, synchronous activity (Markram et al., 2004). A single PV+ interneuron innervates hundreds of pyramidal neurons in the mature cortex (Somogyi et al., 1998). Studies have shown that PV interneurons regulate the developmental increase in inhibition that eventually leads to decrease plasticity, and triggers the closure of the critical period in the visual cortex (Heimel et al., 2011). Perturbations in the GABAergic system is linked to alterations in E/I balance, disruption in the critical period, improper development, and function of neural circuits. This leads to aberrant information processing, and cognitive deficits in a variety of neuro-developmental disorders. This review focuses on the GABAergic system dysfunction in Down syndrome, Rett syndrome, Fragile X syndrome, and Autism and therapeutic strategies.
Down syndrome
Down syndrome (DS) is the most common non-inherited cause of intellectual disability and results from triplication of chromosome 21. The cognitive phenotypes of DS are reproduced in Ts65Dn mice, a model of Down syndrome and are posited to result from imbalance in excitation and inhibition. Several genes involved in the GABAergic systems are present on chromosome 21 and are triplicated in DS and the Ts65Dn mice. These include Olig1/2 and Grik2. Olig1 and Olig2 are over-expressed in the medial ganglionic eminence (MGE) of Ts65Dn brain at E14.5 (Chakrabarti et al., 2010). There are more Olig2+ cells in the Ts65Dn MGE compared to euploid littermates at E13.5 and E14.5 when cohorts of cortical interneurons arise. Olig1/Olig2 over-expression is thought to be the genetic basis of the interneuron over-production in the Ts65Dn brain. Reducing the gene dosage of Olig2 in Ts65Dn mice rescued the interneuron over-production phenotype, and normalized the frequency of spontaneous inhibitory postsynaptic currents (sIPSC). G-protein coupled inward-rectifying potassium (GIRK2) containing channels are over-expressed in Ts65Dn mice (Harashima et al., 2006). These channels are activated by agonists at Gi/o coupled receptors such as the GABAB receptor (Sodickson and Bean, 1996). Their pattern of expression mirrors the expression of GABAB receptors and Grik2, and GABAB receptors are more intensely expressed in the stratum lacunosum moleculare (SLM) when compared to the other layers of the CA1 (Sloviter et al., 1999; Lopez-Bendito et al., 2004; Harashima et al., 2006). The SLM is expected to have larger synaptically evoked inhibitory currents (Pham et al., 1998) and likely serve as primary modulators of the direct perforant pathway inputs into CA1, thus playing important roles in learning and memory (Sybirska et al., 2000; Brun et al., 2002). Elevated GABAB receptor dependent GIRK channel current density was observed in CA1 of Ts65Dn mice and occurred without differences in GABA release probability was (Best et al., 2007, 2012). In addition, the ratio of monosynaptic GABAB/GIRK to GABAA currents was significantly elevated in Ts65Dn mice upon SLM stimulation in the absence of changes in GABAA subunit expression or function. The experiments described by Best et al. (2012) attribute the altered GABAergic transmission in area CA1 of Ts65Dn mice to increase function of the GABAB/GRIK complexes. In contrast, data from Kleschevnikov et al., demonstrates enhanced GABAA and GABAB receptor-mediated evoked IPSCs in the DG granule cells with decrease in paired-pulse ratio suggesting an increase in presynaptic release (Kleschevnikov et al., 2004). Together these data suggest that there are region specific mechanisms underlying GABAergic signaling deficits within theTs65Dn hippocampus.
Several groups show a decrease in the number of excitatory synapses and a relative increase in the inhibitory synaptic markers in the cortex and hippocampus of adult Ts65Dn mice (Belichenko et al., 2004, 2009; Perez-Cremades et al., 2010). Consistent with these findings the number of inhibitory interneurons is increased in Ts65Dn mice (Chakrabarti et al., 2010). Experiments designed to examine the functional relevance of the increase in synaptic markers show that the rate of sIPSC is higher in the pyramidal cell layer of CA1 in Ts65Dn mice. Moreover, there were no differences in the frequency of mIPSC or in the paired pulse ratio. This finding is consistent with an increase in the number of functional interneurons and is inconsistent with an increase in number of inhibitory synapses or enhanced probability of GABA release in CA1 (Chakrabarti et al., 2010; Best et al., 2012; Mitra et al., 2012). Developmental assessment of the IPSC shows a transient increase in evoked inhibition and mIPSC in Ts65Dn mice during the second postnatal week but not in the first or third postnatal week, when stimulation is performed in the stratum radiatum or pyramidale (Mitra et al., 2012). This transient disruption in inhibitory synaptic transmission occurs during the critical period of neuronal network development and could contribute to later network dysfunction seen in adult mice.
Enhanced GABA-mediated inhibition in several hippocampal sub-regions is associated with a marked reduction in long-term potentiation (LTP) in the CA1 and DG. Several groups have rescued LTP upon acute or chronic treatment of Ts65Dn hippocampus with GABA antagonist (Siarey et al., 1997; Kleschevnikov et al., 2004; Costa and Grybko, 2005; Fernandez and Garner, 2008). Consistent with these findings and a role for GABA in learning and memory, modulators of GABA receptor function have been used to rescue cognitive phenotypes in the Ts65Dn mice. The non-competitive GABAA antagonist pentylenetetrazole (PTZ), and the GABA antagonist picrotoxin and bilobalide normalized cognitive function measured by object recognition (Fernandez et al., 2007), while chronic administration of PTZ rescued the performance of Ts65Dn mice in Morris water maze (Rueda et al., 2008). Moreover, RO4938581 (3-bromo-10-(difluoromethyl)-9H-benzo_f_imidazo[1,5-a][1,2,4] triazolo[1,5-d][1,4]diazepine), a selective GABA A _5 NAM, rescued hippocampal LTP and hippocampal dependent cognitive deficits in Ts65Dn mice (Martinez-Cue et al., 2013), and the GABA-A-benzodiazepine receptor inverse agonist selective for the a5-subtype (a5IA) restored learning and memory in novel object and Morris water maze in Ts mice (Braudeau et al., 2011). GABAB receptor antagonism relevant to DS since the GABAB receptor antagonist CGP55845 improved contextual memory in fear-conditioning task in Ts65Dn mice (Kleschevnikov et al., 2012). Clinical trials are underway to study the effect of GABA antagonism on cognitive phenotypes in DS.
Rett syndrome
Rett syndrome (RS) is the leading genetic cause of intellectual disability in girls. It is caused by mutations in the transcriptional repressor methyl-CpG-binding protein 2 (MeCP2). The MECP2 protein regulates gene expression by DNA methylation and MeCP2-mutant mice recapitulate many of the phenotypes RS. These mice, like girls with RS appear phenotypically normal early during development and then undergo severe regression with resulting impairment in respiratory function, loss of hand use, impairment in language, and motor function. Several studies suggest that an imbalance in excitatory and inhibitory neurotransmission contributes to the behavioral abnormalities in RS (Dani et al., 2005; Asaka et al., 2006; Moretti et al., 2006).
In early postnatal life before respiratory abnormalities become apparent, a shift in the E/I balance toward excitation is seen in the ventrolateral medulla of MeCP2 null mice. This shift results from a disruption in both presynaptic and post-synaptic mechanisms of the excitatory and inhibitory pathways (Medrihan et al., 2008). This is in contrast to the increase in inhibitory and reduction in excitatory inputs to L5 pyramidal neurons in the somatosensory cortex during the second postnatal week, also before onset of overt symptoms. The direction of the shift is brain region specific and this is readily apparent in thalamic networks. In the absence of MeCP2, a reduction in frequency of mIPSC in the ventrobasal complex (VB) of the thalamus is observed during the first through third postnatal week but an increase in frequency of mIPSC was observed from the second through third postnatal week in the reticular thalamic nucleus (RTN) (Zhang et al., 2010). A further example of brain region specific change is the shift of E/I balance in favor of inhibition reported in the visual cortex of MeCP2 null mice. Parvalbumin (PV) levels and the number of PV positive interneurons were increased, while the mRNA of the calcium-binding proteins, calretinin, and calbindin were reduced. In addition, perisomatic boutons were increased in MeCP2 KO mice and this increase was evident at the time of eye opening. PV+ interneurons synapse onto the soma and proximal dendrites of principal cells to control their excitability and adjust the gain of their integrated synaptic response (Markram et al., 2004; Atallah et al., 2012). Maturation of these PV circuits in visual cortex is modulated by sensory experience. Dark-rearing from birth (DR) specifically reduces perisomatic inhibition (Katagiri et al., 2007; Sugiyama et al., 2008) and delays onset of the heightened period of visual cortical plasticity. Dark rearing at P30 in the absence of MeCP2 was sufficient to rescue PV-cell hyper-connectivity and improve visual acuity to near WT levels in the adult MeCP2 null mice. Restoration of visual acuity was associated with normalization of PV levels, a reduction in the number of perisomatic boutons and reduction in spontaneous firing rates of MeCP2 KO mice to that of control WT cells (Durand et al., 2012).
The experiments described above clearly demonstrate a critical role for MeCP2 in regulation of GABAergic transmission. The cellular and molecular mechanisms underlying MeCP2-mediated regulation of GABAergic transmission are diverse and highly circuit dependent. Several studies show that BDNF regulates the formation and maturation of GABAergic synapses (Huang et al., 1999; Marty et al., 2000; Hong et al., 2008), and the reduction of BDNF in single cortical neurons caused a reduction in the frequency of mIPSC without change in peak amplitude (Kohara et al., 2007). Indeed, BDNF is regulated by MeCP2 in an activity dependent manner (Zhou et al., 2006) and BDNF levels are reduced in MeCP2 null mice (Chang et al., 2006; Wang et al., 2006). Intriguingly, MeCP2 null mice that are raised in an enriched environment (EE) starting at P10 show increase in BDNF levels and normalization of LTP and spatial memory when measured in adult mice (Lonetti et al., 2010). The normalization of synaptic plasticity and behavior occurs in the context of an increase in the density of excitatory synapses in the somatosensory cortex with no changes in the density of inhibitory synapses (Lonetti et al., 2010). EE have previously been shown to cause a functional reduction in cortical inhibition (Sale et al., 2007), whether a similar mechanism contributes to the amelioration of behavioral and plasticity deficits in MeCP2 null mice reared in an EE is not known. These data suggest that the interplay between MeCP2 and BDNF on the balance between E/I is complex and can be further modulated by environmental context.
Fragile X syndrome
Fragile X syndrome (FXS) is the most common single gene cause of intellectual disability and autism (Kaufmann et al., 2004; Hagerman et al., 2005). It results from loss of function mutations in the fmr1 gene that encodes FMRP (Verkerk et al., 1991; O'Donnell and Warren, 2002). The FX phenotypes of cognitive impairment, hypersensitivity to sensory stimuli, epilepsy, and characteristics of autism are recapitulated in the Fmr1 knockout (KO) mouse a model of FXS (Musumeci et al., 2000; Nielsen et al., 2002; Spencer et al., 2005; Brennan et al., 2006). An imbalance in excitation and inhibition is posited to be central to the etiologic mechanisms of Fragile X.
Several studies have suggested a role for disruption of the GABAergic system in FXS and report abnormal GABA-mediated transmission in FX KO mice. Impairment in the excitatory inputs onto fast spiking (FS) interneurons and impairment in group 1 mGluR activation of low-threshold-spiking (LTS) interneurons have been reported in FX mice (Gibson et al., 2008; Paluszkiewicz et al., 2011). The inhibitory output of the FS and LTS interneurons typically increase in response to network activation (Kapfer et al., 2007; Silberberg and Markram, 2007), thus making them well positioned to dynamically control cortical network function. In FX mice this disruption in activation of FS and LTS is implicated in cortical hyperexcitability manifesting as altered UP States and inhibitory network dysfunction in layerII/III of the somatosensory cortex.
GABAA receptors are heteropentamers, and their subunit composition is an important determinant of inhibitory transmission, subcellular localization, and sensitivity to clinically relevant compounds (Hevers and Luddens, 1998; Sieghart and Sperk, 2002; Rudolph and Mohler, 2006). Expression studies reveal that mRNAs that encode the GABAA α1, α3, α4 receptor subunits are decreased in adult Fmr1 KO mice (El Idrissi et al., 2005; Gantois et al., 2006; D'Hulst et al., 2009). Protein levels of GABAA receptor α1, β2, and δ subunits are transiently down regulated at postnatal day 12 and all but GABAA β2 subunits were restored to normal levels in adult mice. GABAA receptor α1 subunit is the most abundant of all GABAA receptor subunits (Mohler, 2007; Olsen and Sieghart, 2009), they account for about half of all GABAA subunits and are widely expressed in the CNS. The reduction of GABAA receptors at P12 is posited to cause a reduction in excitation in the second week of postnatal development at a time when GABAergic synaptic activity is thought to play a critical role in the maturation of functional inhibitory synapses (Ben-Ari, 2002; Cancedda et al., 2007). Thus, the down regulation of the GABAA receptor subunits at P12 may lead to structural alterations of synapses that result in the characteristic presence of immature dendritic spines in FXS.
Presynaptic increases and decreases in the expression of the GABA-synthesizing enzyme GAD have been reported in Fmr1 KOs (El Idrissi et al., 2005; D'Hulst and Kooy, 2009; Adusei et al., 2010; Olmos-Serrano et al., 2010). The direction of the change is due in part to the brain region examined. Olmos-Serrano and colleagues report that GAD65/67 protein expression is reduced in the basolateral amygdala, and this finding is complemented by decreased vesicular GABA levels. In contrast GAD65/67 levels were increased in the cortex, hippocampus, brainstem, and diencephalon (El Idrissi et al., 2005; Adusei et al., 2010). Transient down regulation of the catabolic enzymes GABA-T and succinic semialdehyde dehydrogenase are reported in the forebrain of FMRP null mice at P12 (Adusei et al., 2010) and may compensate for the decrease levels of GABAA receptor subunits to effectively increase GABAergic transmission by increasing GABA levels.
FMRP KO mice exhibit variable and region specific disruptions in functional inhibitory transmission in behaviorally relevant brain regions. Inhibitory dysfunction in the basolateral amygdala is characterized by reductions in the frequency and amplitude of spontaneous IPSCs and changes in IPSC kinetics. These findings are consistent with report of decreased GABAA receptor subunit, GAD expression, vesicular GABA, and impaired GABA release (Olmos-Serrano et al., 2010). In contrast, striatal neurons demonstrate an increase in basal inhibitory transmission driven by increased GABA release as show by the increase in the frequency of sIPSCs, mIPSCs, and reduction in PPR of evoked IPSCs (Centonze et al., 2008).
GABAergic dysfunction in FMRP KO mice is mediated by presynaptic and post synaptic mechanisms that are brain region and receptor subtype dependent. With this in mind preclinical and clinical trials have examined the therapeutic relevance of GABAA and GABAB receptors in FXS. THIP (gaboxadol), a GABAA receptor agonist, that acts upon tonic GABA receptors significantly attenuated hyperactivity and prepulse inhibition in Fmr1 KO mice, but did not reverse the deficits in cued fear or startle response (Olmos-Serrano et al., 2011). Activation of the GABAB receptor with STX209 (arbaclofen, R-baclofen) corrected synaptic abnormalities, reduces protein synthesis, correct enhanced AMPAR trafficking, and suppressed audiogenic seizures in FMRP KO mice (Pacey et al., 2009; Henderson et al., 2012). Moreover, STX209 when used in a clinical trial showed improved social function in patients with FXS (Berry-Kravis et al., 2012). Additional clinical trials are underway to test the ability of STX209 to reduce aggression and irritability in FXS. The variable mechanism by which GABA dysfunction contributes to the FX phenotype poses interesting challenges to treatment that may require the use of combination therapies.
Autism
Autism Spectrum Disorder is postulated to result in part from deficient GABA neurotransmission. Reduced GABAA receptors and benzodiazapine binding sites are reported in the hippocampus and cingulate gyrus from neuropathological samples from individuals with autism (Blatt et al., 2001; Oblak et al., 2009, 2010). Consistent with the findings in autopsy samples, direct measurement of GABAA receptors and GABA concentration in the living brain of children with ASD using SPECT (Single Photon Emission Computed Tomography) and [1H]MRS showed a reduction in GABAA receptor levels and GABA concentration in the frontal cortex (Harada et al., 2011; Mori et al., 2012). Examination of GABAA receptor levels in the brains of adults with ASD, using Positron Emission Tomography (PET) and the benzodiazepine receptor PET ligand [11C]Ro15-4513, showed a reduction in 11C] Ro15-4513 binding in the amygdala and nucleus accumbens (Mendez et al., 2013).
Converging on neuropathological and imaging data, genetic studies reveal a role for GABAergic dysfunction in ASD. Microduplications/deletions of the 15q11- q13 chromosomal locus, known to contain GABAA a5, b3, and g3 subunits, have been observed in some individuals with ASD (Cook et al., 1998; Menold et al., 2001; Buxbaum et al., 2002; Shao et al., 2003; McCauley et al., 2004; Sebat et al., 2007). Duplication of this locus is expected to result in over expression of the GABAA receptor subunits, however, in vitro studies using human neuronal cell line carrying the 15q duplication showed a reduction in GABRB3 expression (Meguro-Horike et al., 2011). The association of genetic polymorphisms in the DLX1/2 genes provides additional support of the GABAergic model for autism (Liu et al., 2009). In addition, transciptomic analysis of autopsy samples from autistic brains found reduced cortical mRNA expression of genes that are highly expressed in PV+ interneurons (Voineagu et al., 2011). Together these studies provide strong convergent evidence for an inhibitory deficit in autism.
Conclusion
The volume of evidence in support of GABAergic dysfunction in neuro-developmental disorders is overwhelming. Although the mechanism and manifestation of GABA dysfunction is disease and brain region/circuit specific, current evidence supports impaired GABA transmission during the critical period followed by GABAergic dysfunction in the adult animal. Current efforts to treat the disorders discussed have had variable results. One approach worthy of consideration involves reintroducing a period of elevated plasticity in the adult animal. Such approach has major hurdles. It requires a detailed understanding of GABAergic dysfunction, methods for reopening the critical period sub-serving the acquisition of different skills and the impact of such manipulations on other brain regions. Much can be learned from efforts to treat amblyopia by re-opening the critical period. Several groups have reintroduced juvenile plasticity in the adult brain of rodents by directly removing the perineuronal nets (PNN), a structural barrier to plasticity thus enabling recovery from amblyopia (Pizzorusso et al., 2002; Sale et al., 2007; Soleman et al., 2013). Manipulations that adjust the E/I balance either by direct transplantation of embryonic GABA precursor cells into the postnatal brain (Southwell et al., 2010) or the endogenous release of serotonin through chronic treatment with fluoxetine have opened a second critical period that restores visual function in amblyopic adult rats (Maya Vetencourt et al., 2008). Chronic administration of fluoxetine mediates its effect through the reduction of intracortical inhibition and increase in BDNF levels (Maya Vetencourt et al., 2008) possibly allowing activation of plasticity genes and modulation of neuronal circuits involved in ocular dominance. Environmental enrichment through enhanced sensory-motor stimulation rescued spatial learning and visual acuity in adult Ts65Dn mice (Begenisic et al., 2011). These changes occur in association with a reduction in GABA release and normalization of hippocampal LTP. These findings are consistent with previous reports that show reduced cortical inhibition and increased neuronal plasticity in the brains of adult rats exposed to an EE (Sale et al., 2007). Moreover, the restoration of near normal visual acuity in MeCP2 null mice upon dark rearing at P30 is encouraging, and suggests that reopening the critical period maybe a therapeutic option for neuro-developmental disorders. There has been some success at restoring vision in human adults with amblyopia (Bavelier et al., 2010) but the need to better understand the extent to which sensitive periods can be safely and noninvasively recapitulated remains an exciting challenge.
Conflict of interest statement
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Statements
Conflict of interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AduseiD. C.PaceyL. K.ChenD.HampsonD. R. (2010). Early developmental alterations in GABAergic protein expression in fragile X knockout mice. Neuropharmacology59, 167–171. 10.1016/j.neuropharm.2010.05.002
2
AsakaY.JugloffD. G.ZhangL.EubanksJ. H.FitzsimondsR. M. (2006). Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome. Neurobiol. Dis. 21, 217–227. 10.1016/j.nbd.2005.07.005
3
AtallahB. V.BrunsW.CarandiniM.ScanzianiM. (2012). Parvalbumin-expressing interneurons linearly transform cortical responses to visual stimuli. Neuron73, 159–170. 10.1016/j.neuron.2011.12.013
4
BavelierD.LeviD. M.LiR. W.DanY.HenschT. K. (2010). Removing brakes on adult brain plasticity: from molecular to behavioral interventions. J. Neurosci. 30, 14964–14971. 10.1523/JNEUROSCI.4812-10.2010
5
BegenisicT.SpolidoroM.BraschiC.BaroncelliL.MilaneseM.PietraG.et al. (2011). Environmental enrichment decreases GABAergic inhibition and improves cognitive abilities, synaptic plasticity, and visual functions in a mouse model of Down syndrome. Front. Cell. Neurosci. 5:29. 10.3389/fncel.2011.00029
6
BelichenkoN. P.BelichenkoP. V.KleschevnikovA. M.SalehiA.ReevesR. H.MobleyW. C. (2009). The “Down syndrome critical region” is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J. Neurosci. 29, 5938–5948. 10.1523/JNEUROSCI.1547-09.2009
7
BelichenkoP. V.MasliahE.KleschevnikovA. M.VillarA. J.EpsteinC. J.SalehiA.et al. (2004). Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome. J. Comp. Neurol. 480, 281–298. 10.1002/cne.20337
8
Ben-AriY. (2002). Excitatory actions of gaba during development: the nature of the nurture. Nat. Rev. Neurosci. 3, 728–739. 10.1038/nrn920
9
Berry-KravisE. M.HesslD.RathmellB.ZarevicsP.CherubiniM.Walton-BowenK.et al. (2012). Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci. Transl. Med. 4, 152ra127. 10.1126/scitranslmed.3004214
10
BestT. K.CramerN. P.ChakrabartiL.HaydarT. F.GaldzickiZ. (2012). Dysfunctional hippocampal inhibition in the Ts65Dn mouse model of Down syndrome. Exp. Neurol. 233, 749–757. 10.1016/j.expneurol.2011.11.033
11
BestT. K.SiareyR. J.GaldzickiZ. (2007). Ts65Dn, a mouse model of Down syndrome, exhibits increased GABAB-induced potassium current. J. Neurophysiol. 97, 892–900. 10.1152/jn.00626.2006
12
BlattG. J.FitzgeraldC. M.GuptillJ. T.BookerA. B.KemperT. L.BaumanM. L. (2001). Density and distribution of hippocampal neurotransmitter receptors in autism: an autoradiographic study. J. Autism Dev. Disord. 31, 537–543. 10.1023/A:1013238809666
13
BraudeauJ.DelatourB.DuchonA.PereiraP. L.DauphinotL.de ChaumontF.et al. (2011). Specific targeting of the GABA-A receptor alpha5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. J. Psychopharmacol. 25, 1030–1042. 10.1177/0269881111405366
14
BrennanF. X.AlbeckD. S.PaylorR. (2006). Fmr1 knockout mice are impaired in a leverpress escape/avoidance task. Genes Brain Behav. 5, 467–471. 10.1111/j.1601-183X.2005.00183.x
15
BrunV. H.OtnassM. K.MoldenS.SteffenachH. A.WitterM. P.MoserM. B.et al. (2002). Place cells and place recognition maintained by direct entorhinal-hippocampal circuitry. Science296, 2243–2246. 10.1126/science.1071089
16
BuxbaumJ. D.SilvermanJ. M.SmithC. J.GreenbergD. A.KilifarskiM.ReichertJ.et al. (2002). Association between a GABRB3 polymorphism and autism. Mol. Psychiatry7, 311–316. 10.1038/sj.mp.4001011
17
CanceddaL.FiumelliH.ChenK.PooM. M. (2007). Excitatory GABA action is essential for morphological maturation of cortical neurons in vivo. J. Neurosci. 27, 5224–5235. 10.1523/JNEUROSCI.5169-06.2007
18
CentonzeD.RossiS.MercaldoV.NapoliI.CiottiM. T.De ChiaraV.et al. (2008). Abnormal striatal GABA transmission in the mouse model for the fragile X syndrome. Biol. Psychiatry63, 963–973. 10.1016/j.biopsych.2007.09.008
19
ChakrabartiL.BestT. K.CramerN. P.CarneyR. S.IsaacJ. T.GaldzickiZ.et al. (2010). Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome. Nat. Neurosci. 13, 927–934. 10.1038/nn.2600
20
ChangQ.KhareG.DaniV.NelsonS.JaenischR. (2006). The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron49, 341–348. 10.1016/j.neuron.2005.12.027
21
CookE. H.Jr.CourchesneR. Y.CoxN. J.LordC.GonenD.GuterS. J.et al. (1998). Linkage-disequilibrium mapping of autistic disorder, with 15q11-13 markers. Am. J. Hum. Genet. 62, 1077–1083. 10.1086/301832
22
CostaA. C.GrybkoM. J. (2005). Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome. Neurosci. Lett. 382, 317–322. 10.1016/j.neulet.2005.03.031
23
DaniV. S.ChangQ.MaffeiA.TurrigianoG. G.JaenischR.NelsonS. B. (2005). Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. Proc. Natl. Acad. Sci. U.S.A. 102, 12560–12565. 10.1073/pnas.0506071102
24
D'HulstC.AtackJ. R.KooyR. F. (2009). The complexity of the GABAA receptor shapes unique pharmacological profiles. Drug Discov. Today14, 866–875. 10.1016/j.drudis.2009.06.009
25
D'HulstC.KooyR. F. (2009). Fragile X syndrome: from molecular genetics to therapy. J. Med. Genet. 46, 577–584. 10.1136/jmg.2008.064667
26
DurandS.PatriziA.QuastK. B.HachigianL.PavlyukR.SaxenaA.et al. (2012). NMDA receptor regulation prevents regression of visual cortical function in the absence of Mecp2. Neuron76, 1078–1090. 10.1016/j.neuron.2012.12.004
27
El IdrissiA.DingX. H.ScaliaJ.TrenknerE.BrownW. T.DobkinC. (2005). Decreased GABA(A) receptor expression in the seizure-prone fragile X mouse. Neurosci. Lett. 377, 141–146. 10.1016/j.neulet.2004.11.087
28
FernandezF.GarnerC. C. (2008). Episodic-like memory in Ts65Dn, a mouse model of Down syndrome. Behav. Brain Res. 188, 233–237. 10.1016/j.bbr.2007.09.015
29
FernandezF.MorishitaW.ZunigaE.NguyenJ.BlankM.MalenkaR. C.et al. (2007). Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat. Neurosci. 10, 411–413. 10.1038/nn1860
30
GantoisI.VandesompeleJ.SpelemanF.ReyniersE.D'HoogeR.SeverijnenL. A.et al. (2006). Expression profiling suggests underexpression of the GABA(A) receptor subunit delta in the fragile X knockout mouse model. Neurobiol. Dis. 21, 346–357. 10.1016/j.nbd.2005.07.017
31
GibsonJ. R.BartleyA. F.HaysS. A.HuberK. M. (2008). Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome. J. Neurophysiol. 100, 2615–2626. 10.1152/jn.90752.2008
32
HagermanR. J.OnoM. Y.HagermanP. J. (2005). Recent advances in fragile X: a model for autism and neurodegeneration. Curr. Opin. Psychiatry18, 490–496. 10.1097/01.yco.0000179485.39520.b0
33
HaradaM.TakiM. M.NoseA.KuboH.MoriK.NishitaniH.et al. (2011). Non-invasive evaluation of the GABAergic/glutamatergic system in autistic patients observed by MEGA-editing proton MR spectroscopy using a clinical 3 tesla instrument. J. Autism Dev. Disord. 41, 447–454. 10.1007/s10803-010-1065-0
34
HarashimaC.JacobowitzD. M.WittaJ.BorkeR. C.BestT. K.SiareyR. J.et al. (2006). Abnormal expression of the G-protein-activated inwardly rectifying potassium channel 2 (GIRK2) in hippocampus, frontal cortex, and substantia nigra of Ts65Dn mouse: a model of Down syndrome. J. Comp. Neurol. 494, 815–833. 10.1002/cne.20844
35
HeimelJ. A.van VersendaalD.LeveltC. N. (2011). The role of GABAergic inhibition in ocular dominance plasticity. Neural Plast. 2011, 391763. 10.1155/2011/391763
36
HendersonC.WijetungeL.KinoshitaM. N.ShumwayM.HammondR. S.PostmaF. R.et al. (2012). Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci. Transl. Med. 4, 152ra128. 10.1126/scitranslmed.3004218
37
HenschT. K. (2005). Critical period plasticity in local cortical circuits. Nat. Rev. Neurosci. 6, 877–888. 10.1038/nrn1787
38
HeversW.LuddensH. (1998). The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes. Mol. Neurobiol. 18, 35–86. 10.1007/BF02741459
39
HongE. J.McCordA. E.GreenbergM. E. (2008). A biological function for the neuronal activity-dependent component of Bdnf transcription in the development of cortical inhibition. Neuron60, 610–624. 10.1016/j.neuron.2008.09.024
40
HuangZ. J.KirkwoodA.PizzorussoT.PorciattiV.MoralesB.BearM. F.et al. (1999). BDNF regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex. Cell98, 739–755. 10.1016/S0092-8674(00)81509-3
41
KapferC.GlickfeldL. L.AtallahB. V.ScanzianiM. (2007). Supralinear increase of recurrent inhibition during sparse activity in the somatosensory cortex. Nat. Neurosci. 10, 743–753. 10.1038/nn1909
42
KatagiriH.FagioliniM.HenschT. K. (2007). Optimization of somatic inhibition at critical period onset in mouse visual cortex. Neuron53, 805–812. 10.1016/j.neuron.2007.02.026
43
KaufmannW. E.CortellR.KauA. S.BukelisI.TierneyE.GrayR. M.et al. (2004). Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors. Am. J. Med. Genet. A129A, 225–234. 10.1002/ajmg.a.30229
44
KleschevnikovA. M.BelichenkoP. V.GallJ.GeorgeL.NoshenyR.MaloneyM. T.et al. (2012). Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome. Neurobiol. Dis. 45, 683–691. 10.1016/j.nbd.2011.10.009
45
KleschevnikovA. M.BelichenkoP. V.VillarA. J.EpsteinC. J.MalenkaR. C.MobleyW. C. (2004). Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J. Neurosci. 24, 8153–8160. 10.1523/JNEUROSCI.1766-04.2004
46
KnudsenE. I. (2004). Sensitive periods in the development of the brain and behavior. J. Cogn. Neurosci. 16, 1412–1425. 10.1162/0898929042304796
47
KoharaK.YasudaH.HuangY.AdachiN.SohyaK.TsumotoT. (2007). A local reduction in cortical GABAergic synapses after a loss of endogenous brain-derived neurotrophic factor, as revealed by single-cell gene knock-out method. J. Neurosci. 27, 7234–7244. 10.1523/JNEUROSCI.1943-07.2007
48
KullmannD. M. (2011). Interneuron networks in the hippocampus. Curr. Opin. Neurobiol. 21, 709–716. 10.1016/j.conb.2011.05.006
49
LiuX.NovosedlikN.WangA.HudsonM. L.CohenI. L.ChudleyA. E.et al. (2009). The DLX1and DLX2 genes and susceptibility to autism spectrum disorders. Eur. J. Hum. Genet. 17, 228–235. 10.1038/ejhg.2008.148
50
LonettiG.AngelucciA.MorandoL.BoggioE. M.GiustettoM.PizzorussoT. (2010). Early environmental enrichment moderates the behavioral and synaptic phenotype of MeCP2 null mice. Biol. Psychiatry67, 657–665. 10.1016/j.biopsych.2009.12.022
51
Lopez-BenditoG.ShigemotoR.KulikA.VidaI.FairenA.LujanR. (2004). Distribution of metabotropic GABA receptor subunits GABAB1a/b and GABAB2 in the rat hippocampus during prenatal and postnatal development. Hippocampus14, 836–848. 10.1002/hipo.10221
52
MarkramH.Toledo-RodriguezM.WangY.GuptaA.SilberbergG.WuC. (2004). Interneurons of the neocortical inhibitory system. Nat. Rev. Neurosci. 5, 793–807. 10.1038/nrn1519
53
Martinez-CueC.MartinezP.RuedaN.VidalR.GarciaS.VidalV.et al. (2013). Reducing GABAA alpha5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome. J. Neurosci. 33, 3953–3966. 10.1523/JNEUROSCI.1203-12.2013
54
MartyS.WehrleR.SoteloC. (2000). Neuronal activity and brain-derived neurotrophic factor regulate the density of inhibitory synapses in organotypic slice cultures of postnatal hippocampus. J. Neurosci. 20, 8087–8095.
55
Maya VetencourtJ. F.SaleA.ViegiA.BaroncelliL.De PasqualeR.O'LearyO. F.et al. (2008). The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science320, 385–388. 10.1126/science.1150516
56
McCauleyJ. L.OlsonL. M.DelahantyR.AminT.NurmiE. L.OrganE. L.et al. (2004). A linkage disequilibrium map of the 1-Mb 15q12 GABA(A) receptor subunit cluster and association to autism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 131B, 51–59. 10.1002/ajmg.b.30038
57
MedrihanL.TantalakiE.AramuniG.SargsyanV.DudanovaI.MisslerM.et al. (2008). Early defects of GABAergic synapses in the brain stem of a MeCP2 mouse model of Rett syndrome. J. Neurophysiol. 99, 112–121. 10.1152/jn.00826.2007
58
Meguro-HorikeM.YasuiD. H.PowellW.SchroederD. I.OshimuraM.LasalleJ. M.et al. (2011). Neuron-specific impairment of inter-chromosomal pairing and transcription in a novel model of human 15q-duplication syndrome. Hum. Mol. Genet. 20, 3798–3810. 10.1093/hmg/ddr298
59
MendezM. A.HorderJ.MyersJ.CoghlanS.StokesP.ErritzoeD.et al. (2013). The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15-4513 positron emission tomography study. Neuropharmacology68, 195–201. 10.1016/j.neuropharm.2012.04.008
60
MenoldM. M.ShaoY.WolpertC. M.DonnellyS. L.RaifordK. L.MartinE. R.et al. (2001). Association analysis of chromosome 15 gabaa receptor subunit genes in autistic disorder. J. Neurogenet. 15, 245–259. 10.3109/01677060109167380
61
MitraA.BlankM.MadisonD. V. (2012). Developmentally altered inhibition in Ts65Dn, a mouse model of Down syndrome. Brain Res. 1440, 1–8. 10.1016/j.brainres.2011.12.034
62
MohlerH. (2007). Molecular regulation of cognitive functions and developmental plasticity: impact of GABAA receptors. J. Neurochem. 102, 1–12. 10.1111/j.1471-4159.2007.04454.x
63
MorettiP.LevensonJ. M.BattagliaF.AtkinsonR.TeagueR.AntalffyB.et al. (2006). Learning and memory and synaptic plasticity are impaired in a mouse model of Rett syndrome. J. Neurosci. 26, 319–327. 10.1523/JNEUROSCI.2623-05.2006
64
MoriT.MoriK.FujiiE.TodaY.MiyazakiM.HaradaM.et al. (2012). Evaluation of the GABAergic nervous system in autistic brain: (123)I-iomazenil SPECT study. Brain Dev. 34, 648–654. 10.1016/j.braindev.2011.10.007
65
MusumeciS. A.BoscoP.CalabreseG.BakkerC.De SarroG. B.EliaM.et al. (2000). Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. Epilepsia41, 19–23. 10.1111/j.1528-1157.2000.tb01499.x
66
NielsenD. M.DerberW. J.McClellanD. A.CrnicL. S. (2002). Alterations in the auditory startle response in Fmr1 targeted mutant mouse models of fragile X syndrome. Brain Res. 927, 8–17. 10.1016/S0006-8993(01)03309-1
67
OblakA.GibbsT. T.BlattG. J. (2009). Decreased GABAA receptors and benzodiazepine binding sites in the anterior cingulate cortex in autism. Autism Res. 2, 205–219. 10.1002/aur.88
68
OblakA. L.GibbsT. T.BlattG. J. (2010). Decreased GABA(B) receptors in the cingulate cortex and fusiform gyrus in autism. J. Neurochem. 114, 1414–1423. 10.1111/j.1471-4159.2010.06858.x
69
O'DonnellW. T.WarrenS. T. (2002). A decade of molecular studies of fragile X syndrome. Annu. Rev. Neurosci. 25, 315–338. 10.1146/annurev.neuro.25.112701.142909
70
Olmos-SerranoJ. L.CorbinJ. G.BurnsM. P. (2011). The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome. Dev. Neurosci. 33, 395–403. 10.1159/000332884
71
Olmos-SerranoJ. L.PaluszkiewiczS. M.MartinB. S.KaufmannW. E.CorbinJ. G.HuntsmanM. M. (2010). Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J. Neurosci. 30, 9929–9938. 10.1523/JNEUROSCI.1714-10.2010
72
OlsenR. W.SieghartW. (2009). GABA A receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology56, 141–148. 10.1016/j.neuropharm.2008.07.045
73
PaceyL. K.HeximerS. P.HampsonD. R. (2009). Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Mol. Pharmacol. 76, 18–24. 10.1124/mol.109.056127
74
PaluszkiewiczS. M.Olmos-SerranoJ. L.CorbinJ. G.HuntsmanM. M. (2011). Impaired inhibitory control of cortical synchronization in fragile X syndrome. J. Neurophysiol. 106, 2264–2272. 10.1152/jn.00421.2011
75
Perez-CremadesD.HernandezS.Blasco-IbanezJ. M.CrespoC.NacherJ.VareaE. (2010). Alteration of inhibitory circuits in the somatosensory cortex of Ts65Dn mice, a model for Down's syndrome. J. Neural Transm. 117, 445–455. 10.1007/s00702-010-0376-9
76
PhamT. M.NurseS.LacailleJ. C. (1998). Distinct GABAB actions via synaptic and extrasynaptic receptors in rat hippocampus in vitro. J. Neurophysiol. 80, 297–308.
77
PizzorussoT.MediniP.BerardiN.ChierziS.FawcettJ. W.MaffeiL. (2002). Reactivation of ocular dominance plasticity in the adult visual cortex. Science298, 1248–1251. 10.1126/science.1072699
78
RudolphU.MohlerH. (2006). GABA-based therapeutic approaches: GABAA receptor subtype functions. Curr. Opin. Pharmacol. 6, 18–23. 10.1016/j.coph.2005.10.003
79
RuedaN.FlorezJ.Martinez-CueC. (2008). Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Neurosci. Lett. 433, 22–27. 10.1016/j.neulet.2007.12.039
80
SaleA.Maya VetencourtJ. F.MediniP.CenniM. C.BaroncelliL.De PasqualeR.et al. (2007). Environmental enrichment in adulthood promotes amblyopia recovery through a reduction of intracortical inhibition. Nat. Neurosci. 10, 679–681. 10.1038/nn1899
81
SebatJ.LakshmiB.MalhotraD.TrogeJ.Lese-MartinC.WalshT.et al. (2007). Strong association of de novo copy number mutations with autism. Science316, 445–449. 10.1126/science.1138659
82
ShaoY.CuccaroM. L.HauserE. R.RaifordK. L.MenoldM. M.WolpertC. M.et al. (2003). Fine mapping of autistic disorder to chromosome 15q11-q13 by use of phenotypic subtypes. Am. J. Hum. Genet. 72, 539–548. 10.1086/367846
83
SiareyR. J.StollJ.RapoportS. I.GaldzickiZ. (1997). Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down Syndrome. Neuropharmacology36, 1549–1554. 10.1016/S0028-3908(97)00157-3
84
SieghartW.SperkG. (2002). Subunit composition, distribution and function of GABA(A) receptor subtypes. Curr. Top. Med. Chem. 2, 795–816. 10.2174/1568026023393507
85
SilberbergG.MarkramH. (2007). Disynaptic inhibition between neocortical pyramidal cells mediated by Martinotti cells. Neuron53, 735–746. 10.1016/j.neuron.2007.02.012
86
SloviterR. S.Ali-AkbarianL.ElliottR. C.BoweryB. J.BoweryN. G. (1999). Localization of GABA(B) (R1) receptors in the rat hippocampus by immunocytochemistry and high resolution autoradiography, with specific reference to its localization in identified hippocampal interneuron subpopulations. Neuropharmacology38, 1707–1721. 10.1016/S0028-3908(99)00132-X
87
SodicksonD. L.BeanB. P. (1996). GABAB receptor-activated inwardly rectifying potassium current in dissociated hippocampal CA3 neurons. J. Neurosci. 16, 6374–6385.
88
SolemanS.FilippovM. A.DityatevA.FawcettJ. W. (2013). Targeting the neural extracellular matrix in neurological disorders. Neuroscience253, 194–213. 10.1016/j.neuroscience.2013.08.050
89
SomogyiP.KlausbergerT. (2005). Defined types of cortical interneurone structure space and spike timing in the hippocampus. J. Physiol. 562, 9–26. 10.1113/jphysiol.2004.078915
90
SomogyiP.TamasG.LujanR.BuhlE. H. (1998). Salient features of synaptic organisation in the cerebral cortex. Brain Res. Brain Res. Rev. 26, 113–135. 10.1016/S0165-0173(97)00061-1
91
SouthwellD. G.FroemkeR. C.Alvarez-BuyllaA.StrykerM. P.GandhiS. P. (2010). Cortical plasticity induced by inhibitory neuron transplantation. Science327, 1145–1148. 10.1126/science.1183962
92
SpencerC. M.AlekseyenkoO.SeryshevaE.Yuva-PaylorL. A.PaylorR. (2005). Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav. 4, 420–430. 10.1111/j.1601-183X.2005.00123.x
93
SugiyamaS.Di NardoA. A.AizawaS.MatsuoI.VolovitchM.ProchiantzA.et al. (2008). Experience-dependent transfer of Otx2 homeoprotein into the visual cortex activates postnatal plasticity. Cell134, 508–520. 10.1016/j.cell.2008.05.054
94
SybirskaE.DavachiL.Goldman-RakicP. S. (2000). Prominence of direct entorhinal-CA1 pathway activation in sensorimotor and cognitive tasks revealed by 2-DG functional mapping in nonhuman primate. J. Neurosci. 20, 5827–5834.
95
VerkerkA. J.PierettiM.SutcliffeJ. S.FuY. H.KuhlD. P.PizzutiA.et al. (1991). Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell65, 905–914. 10.1016/0092-8674(91)90397-H
96
VoineaguI.WangX.JohnstonP.LoweJ. K.TianY.HorvathS.et al. (2011). Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature474, 380–384. 10.1038/nature10110
97
WangH.ChanS. A.OgierM.HellardD.WangQ.SmithC.et al. (2006). Dysregulation of brain-derived neurotrophic factor expression and neurosecretory function in Mecp2 null mice. J. Neurosci. 26, 10911–10915. 10.1523/JNEUROSCI.1810-06.2006
98
WieselT. N.HubelD. H. (1963). Single-cell responses in striate cortex of kittens deprived of vision in one eye. J. Neurophysiol. 26, 1003–1017
99
ZhangZ. W.ZakJ. D.LiuH. (2010). MeCP2 is required for normal development of GABAergic circuits in the thalamus. J. Neurophysiol. 103, 2470–2481. 10.1152/jn.00601.2009
100
ZhouZ.HongE. J.CohenS.ZhaoW. N.HoH. Y.SchmidtL.et al. (2006). Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron52, 255–269. 10.1016/j.neuron.2006.09.037
Summary
Keywords
PV interneurons, synaptic plasticity, critical period, disease, circuits
Citation
Smith-Hicks CL (2013) GABAergic dysfunction in pediatric neuro-developmental disorders. Front. Cell. Neurosci. 7:269. doi: 10.3389/fncel.2013.00269
Received
17 May 2013
Accepted
04 December 2013
Published
19 December 2013
Volume
7 - 2013
Edited by
Graziella DiCristo, University of Montreal, Canada
Reviewed by
Knut Holthoff, Universitätsklinikum Jena, Germany; Alessandro Sale, National Research Council (CNR), Italy
Copyright
© 2013 Smith-Hicks.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Constance L. Smith-Hicks, Neurology, Kennedy Krieger Institute, 707 North Broadway, Baltimore, MD 21205, USA e-mail: hicksc@kennedykrieger.org
This article was submitted to the journal Frontiers in Cellular Neuroscience.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.